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ABSTRACT
The differentiation of mouse embryonic stem cells (ESCs) is controlled by the interaction of multi-
ple signaling pathways, typically mediated by post-translational protein modifications. The addi-
tion of O-linked N-acetylglucosamine (O-GlcNAc) to serine and threonine residues of nuclear and
cytoplasmic proteins is one such modification (O-GlcNAcylation), whose function in ESCs is only
now beginning to be elucidated. Here, we demonstrate that the specific inhibition of O-GlcNAc
hydrolase (Oga) causes increased levels of protein O-GlcNAcylation and impairs differentiation of
mouse ESCs both in serum-free monolayer and in embryoid bodies (EBs). Use of reporter cell lines
demonstrates that Oga inhibition leads to a reduction in the number of Sox1-expressing neural
progenitors generated following induction of neural differentiation as well as maintained expres-
sion of the ESC marker Oct4 (Pou5f1). In EBs, expression of mesodermal and endodermal markers
is also delayed. However, the transition of na€ıve cells to primed pluripotency indicated by Rex1
(Zfp42), Nanog, Esrrb, and Dppa3 downregulation and Fgf5 upregulation remains unchanged.
Finally, we demonstrate that increased O-GlcNAcylation results in upregulation of genes normally
epigenetically silenced in ESCs, supporting the emerging role for this protein modification in the
regulation of histone modifications and DNA methylation. STEM CELLS 2014;32:2605–2615
INTRODUCTION
Over the last decade there have been major
advances in our understanding of the mecha-
nisms controlling embryonic stem cell (ESC)
behavior in response to the changing extracellu-
lar environment [1]. These mechanisms largely
involve engagement of signal transduction
relays that operate by post-translational modifi-
cations of proteins. Under standard conditions,
ESCs grow as a mixture of “na€ıve” and “primed”
cells. Signaling mediated by Erk1/2 target phos-
phorylation has recently been implicated in reg-
ulating the transition between these two states
and initiation of differentiation [2]. Reversible
protein modification by addition of O-linked N-
acetylglucosamine to serine or threonine resi-
dues (O-GlcNAcylation) was first described 30
years ago [3] and occurs with similar time
scales, dynamics, and stoichiometry as protein
phosphorylation, with which it sometimes com-
petes. O-GlcNAcylation is found in all higher
eukaryotes tested to date and has been impli-
cated in development, epigenetic regulation,
and diseases such as diabetes and Alzheimer’s
[4]. Its addition and removal are catalyzed by
one transferase (Ogt) and one hydrolase (Oga;
also known as Mgea5), respectively.
To date there have been very few studies
on O-GlcNAc function in ESCs, although accu-
mulating evidence suggests a critical role for
this modification. Elimination of Ogt in mouse
ESCs or conditional deletion in somatic cells
leads to death, consistent with an essential role
in all cell types [5, 6]. Ogt has recently been
identified as a protein partner of the essential
ESC transcription factor Oct4 (Pou5f1) by three
independent studies [7–9]. Furthermore, Oct4
has been shown to be modified by O-GlcNAc
[10], and this was demonstrated to be impor-
tant for regulation of a subset of its targets in
ESCs and during reprogramming [11]. A previ-
ous study has suggested that increased O-
GlcNAcylation in ESCs prevents differentiation
along the cardiac lineage in spontaneously dif-
ferentiating embryoid bodies (EBs) [12]; how-
ever, the mechanism for this or the stage at
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which differentiation stalled was not determined. Ogt is a mam-
malian homolog of the Drosophila super sex combs (scx) gene,
a member of the Polycomb group of transcriptional repressors
[13, 14] and has established roles in gene repression [15]. Fur-
thermore, recent studies implicate O-GlcNAc transferase in the
regulation of the Tet epigenetic modifiers [16–18], suggesting
that the O-GlcNAc modification and the enzymes controlling it
regulate chromatin in pluripotent cells by multiple
mechanisms.
In this study, we investigate in detail the effects of
increased O-GlcNAcylation on neural differentiation of mouse
ESCs. Our results show that Oga inhibition leads to delayed
onset of differentiation although the transition of na€ıve cells
to primed pluripotency proceeds unhindered. We also present
a genome-wide gene expression analysis of ESCs and differen-
tiating cells treated with a highly specific Oga inhibitor, reveal-
ing that increased O-GlcNAc levels control the expression of
distinct groups of genes in ESCs associated with a recently
described subpopulation resembling the two-cell-stage
embryo. Upregulation of these gene sets is consistent with a
disruption of the normal transcriptional repression pro-
gramme operating in pluripotent cells.
MATERIALS AND METHODS
ESC Culture and Differentiation
Mouse ESCs were cultured without feeders on 0.1% gelatin-
coated plastics in Glasgow Minimal Essential Medium with
10% serum and Leukemia Inhibitory Factor (LIF) [19] and dif-
ferentiation was performed according to our previous protocol
[20]. The cell lines used were derivatives of E14Tg2aIV (46C
[21], OCRG9 [22]) or Oct4GiP [23]. GlcNAcstatin C (GNS) was
obtained from GlycoBioChem (Dundee, UK; www.glycobio
chem.com) and used at 1 mM unless otherwise specified. For
flow cytometry, cells were dissociated using Accutase (Milli-
pore, Billerica, MA; www.emdmillipore.com) and resuspended
in PBS/1% bovine serum albumin (BSA) containing 1 mg/ml
propidium iodide (PI; Sigma, St. Louis, MO; www.sigmaaldrich.
com). Cellular debris and PI-positive cells were excluded from
analysis. For clonal analysis, 600/100 cells were plated per
10 cm dish/well of six-well plate and cultured for 6–8 days,
then fixed, and stained using an Alkaline phosphatase staining
kit (Sigma).
siRNA Induced Knockdown of Oga and Ogt
Cells were seeded into six-well dishes (2 3 105 cells/well).
While still in suspension, cells were transfected with Smart-
Pool siRNAs targeting Oga or Ogt or with a nontargeting
siRNA pool (50 pmol per well, Thermo Scientific, Waltham,
MA; www.thermoscientific.com) using Lipofectamine RNAiMAX
(Life Technologies, Carlsbad, CA; www.lifetechnologies.com) (5
ml per well). Cells were transfected again after 24 hours.
Western Blotting
Cells were cultured or differentiated in 9 cm dishes and treat-
ments were for 24 hours unless otherwise specified. Lysis was
performed on ice in whole-cell lysis buffer (150 mM sodium
chloride, 1.0% Nonidet P40, 50 mM Tris, pH 8.0 with 1 mM
GNS, Complete protease inhibitor, and PhosStop phosphatase
inhibitor cocktail tablets from Roche, Basel, Switzerland; www.
roche.com). For nuclear/cytoplasmic fractionation, cells were
lysed on ice in Buffer A (10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM Dithiothreitol (DTT), 0.05% Nonidet P40
pH 7.9) for 10 minutes and centrifuged for 10 minutes at
3,000 rpm in a microfuge at 4C. The supernatant was
removed as a cytoplasmic fraction and the pellet was resus-
pended in Buffer B (5 mM HEPES, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 26% glycerol [vol/vol], pH 7.9) by micro-
pestle homogenization, NaCl added to 300 mM, and incu-
bated on ice for 30 minutes. A final spin at 12,000g was
performed to separate insoluble material from the nuclear
fraction. Protein concentration was determined by Coomassie
protein assay (Thermo Scientific) and 10–30 mg of protein was
loaded per lane of Life Technologies NuPage gels and trans-
ferred to Polyvinylidene fluoride membrane (Millipore). Mem-
branes were blocked in either 5% Milk (Marvel, Premier
Foods, St. Albans, UK; www.premierfoods.co.uk) in TBST or
1%–5% BSA (Millipore) in TBST (all other chemicals from
Sigma). Antibodies were incubated in blocking buffer over-
night: anti-O-GlcNAc, CTD110.6 (Covance, Princeton, NJ; www.
covance.com, 1/5,000), or RL-2 (Santa Cruz Biotechnology,
Dallas, TX; www.scbt.com, 1/1,000); beta actin (Abcam,
Cambridge, UK; www.abcam.co.uk, 1/2,000); phosphoErk1/2
(Cell Signaling Technologies, Beverly, MA; www.cellsignal.com,
1/1,000); Gsk3a and phosphoGsk3a/b (Cell Signaling,
1/1,000); phospho-Serine and phospho-Threonine (Cell Signal-
ing, 1/1,000); Oct4 (Abcam 1/1,000); Sox2 (Abcam 1/1,000).
For the phospho-kinase antibody array (R&D Systems, Minne-
apolis, MN; www.rndsystems.com) 500 mg of total cell lysate
was used according to manufacturers instructions and the
arrays were developed using LumiGLO from Cell Signaling and
imaged on a Fuji LAS3000 mini scanner. Densitometry was
performed with ImageJ.
Immunoprecipitation
Whole cell lysate (500 mg) was incubated overnight with a
mixture of succinylated wheat germ agglutinin-agarose and
protein A sepharose beads in the presence of antibody RL-2
(anti-O-GlcNAc). After washing the bound proteins were
eluted in 25 ml of 23 LDS loading buffer (Life Technologies),
boiled for 5 minutes, and analyzed by Western blotting.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (PFA) for 15 minutes,
permeabilized in PBS, 0.1% Tween (PBST), and incubated in
PBST 15% BSA (blocking buffer). Primary antibody (goat anti-
Oct4, Santa Cruz) was diluted in blocking buffer at 1/50 and
incubated overnight at 4C. Subsequently, cells were incu-
bated in fluorescent secondary antibody (AlexaFluor conju-
gate, Life Technologies, 1/1,000) and 300 nM 40,6-diamidino-
2-phenylindole for 1 hour.
Two-Dimensional-PAGE
Nuclear samples extracted from ESCs treated with LIF, or 1–4
days treatment with N2B27, were enzymatically labeled using
Click-IT O-GlcNAc labeling system (Life Technologies) according
to the manufacturers instructions. Samples were chloroform-
methanol precipitated and resuspended in 7 M urea, 2 M thi-
ourea, 4% CHAPS, 1% ASB-14, and 0.5% ampholytes. Passive
rehydration was performed overnight followed by isoelectric
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focusing using pH 3–10 NL IPG strips for 4,200 vh. Preceding
equilibration, samples were separated by SDS-PAGE using
4%–12% bis/tris gels and transferred to Polyvinylidene fluo-
ride for detection by streptavidin-HRP. Ten prominent spots
were excised from duplicate gels and analyzed by MALDI-TOF
mass spectrometry.
Quantitative RT-PCR
RNA was extracted from cells grown in six-well plates using
Nucleospin II RNA kit (Macherey-Nagel, Dueren, Germany;
www.mn-net.com). DNase treatment was performed on-
column during RNA extraction. One microgram of RNA was
reverse transcribed with the qScript cDNA synthesis kit
(Quanta Biosciences, Gaithersburg, MD; www.quantabio.com).
PCR was performed on a BioRad iCycler or an AB 7500 using
PerfeCTa SYBR Green FastMix for iQ or PerfeCTa SYBR Green
FastMix Low Rox (both Quanta Biosciences), respectively.
Primer sequences are shown in Supporting Information Table
S1. Relative quantitation was performed using the method by
Pfaffl [24] and b-actin as a reference gene from technical dupli-
cates or triplicates of at least three independent experiments.
Microarray Analysis
RNA samples (from four independent experiments) were proc-
essed and hybridized to Affymetrix Gene 1.1ST arrays by Ark
Genomics (www.ark-genomics.org) and the raw array expression
data were obtained as CEL files. For quality control and probe
sets annotations, the annotations files (Release 32, dated 23-06-
2011) downloaded from Affymetrix (Santa Clara, CA; www.affy
metrix.com) were used. Background noise control (Detected
Above Background), Robust Multi-array Average normalization,
and summarization of probe set level data into transcript clus-
ters were carried out using Affymetrix Power Tools. Quality anal-
ysis and differential expression analyses were performed in
Partek GS 6.5 (version 6.11.0321) software and R (version
2.13.1)—Bioconductor using Limma [25], and RankProd [26]
packages [27]. The microarray data have been deposited in EBI
ArrayExpress under accession number E-MEXP-3593. For gene
set enrichment analysis (GSEA) GSEA v2.0.13 was used, along
with gene sets from MSigDB, GenesigDB, or custom made ones
from the literature (Supporting Information Table S5). Genes
were ranked by the Signal2Noise metric and the weighted2
enrichment statistic was used over 1,000 gene set permutations.
A false discovery rate q-value cut-off of 0.05 was applied.
RESULTS
Protein O-GlcNAcylation Delays Mouse ESC
Differentiation
We decided to investigate the changes in O-GlcNAc signal-
ing during ESC neural differentiation. Global O-GlcNAc levels
decline slightly during the first few days of differentiation,
as measured by Western blotting with the O-GlcNAc-specific
antibody CTD110.6 (Fig. 1A). However, this method may
miss changes in the O-GlcNAcylation of lower abundance
proteins. To test for more subtle changes in protein
O-GlcNAcylation, we performed a two-dimensional-PAGE-
Western blot analysis of nuclear extracts of ESCs and cells
during the first 4 days of monolayer differentiation using
chemoenzymatic labeling of O-GlcNAcylated proteins (Fig.
1B and Supporting Information Fig. S1A). The results
revealed a dynamic pattern of nuclear O-GlcNAcylated pro-
teins, with a dramatic change during the first 24 hours of
differentiation. As the O-GlcNAcylation on the majority of
the nuclear proteins disappeared following 24 hours of dif-
ferentiation, we hypothesized that removal of the O-GlcNAc
modification from some ESC protein(s) may be required for
differentiation onset. We also picked 10 spots showing dra-
matic regulation from the Day 1 gel and identified them
by mass spectrometry. Our analysis identified 26 unique
proteins. Although we were not able to positively identify
O-GlcNAc modification on any of these proteins due to the
instrumentation used, we note that 13 of the 26 had pre-
viously been identified as O-GlcNAc modified by other
screens (Supporting Information Table S2).
We then sought to determine whether the O-GlcNAc lev-
els in ESCs can be modulated by inhibiting the Oga enzyme
activity that removes O-GlcNAc using GNS, a highly potent
and specific small molecule Oga inhibitor that exhibits 164-
fold selectivity for Oga when tested against the closely related
lysosomal hexosaminidases HexA/B [28] and a competitive
inhibitor of the O-GlcNAc transferase Ogt (4Ac5SGlcNAc) [29].
Treatment of ESCs with GNS resulted in a dose-dependent
increase in cellular O-GlcNAc levels (Fig. 1C) including
O-GlcNAcylation of the transcription factor Sox2 on S248 (Fig.
1D), with no discernable effects on cell viability or prolifera-
tion even after prolonged treatment (Fig. 1E, 1F). Similar
results were obtained by use of siRNA (Supporting Informa-
tion Fig. S1B). Inhibition of Ogt conversely led to cell death
within 4–5 days in culture (Supporting Information Fig. S1C),
consistent with the previous observation that this protein is
essential for ESC viability [5] (Fig. 3A).
We then treated murine 46C ESCs (engineered to express
the green fluorescent protein [GFP] from the endogenous
neural-specific Sox1 locus [21]) with GNS during monolayer
differentiation into neural cells [20]. Flow cytometry showed
that a significantly smaller proportion of neural progenitors
were generated during ESC differentiation in the presence of
GNS (24.6% in GNS vs. 32.2% in DMSO at day 3, a reduction
of 23.6%; n5 4, p5 .0118) (Fig. 2A, Supporting Information
Videos S1 and S2). Similar effects were seen using a structur-
ally distinct Oga inhibitor, Thiamet G (21.4% reduction at day
3). Sox1 mRNA levels were similarly reduced (Supporting
Information Fig. S2A). This decrease in neural progenitors
could reflect a bias of differentiation against neural fate, or
be due to a more general effect on the onset of differentia-
tion irrespective of lineage. To test this differentiating 46C
cells were assessed for expression of the ESC marker Oct4.
GNS-treated ESCs remained Oct4 positive when vehicle-
treated control cells have largely lost Oct4 immunoreactivity
and instead expressed Sox1GFP (Fig. 2B). We obtained the
same result using the transgenic Oct4-GFP reporter ESC line
Oct4GiP (Fig. 2C), suggesting a delay in differentiation onset
in the presence of GNS. Consistently, we also observed a
decrease in endoderm (BMP2) and mesoderm (Brachyury,
Eomesodermin) markers following EB differentiation (Fig. 2D–
2F). Interestingly, primitive endoderm differentiation meas-
ured by RT-qPCR for Sox17 and Gata6 appears to be unaf-
fected by GNS (Supporting Information Fig. S2B, S2C).
ESC self-renewal can be maintained through the action of
the transcription factor Stat3, operating downstream of the
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cytokine LIF. However, we could not detect any change in
Stat3 phosphorylation in GNS-treated cells compared to con-
trols (Fig. 3A), which suggests that the effect of raised O-
GlcNAc levels on ESC differentiation is independent of Stat3
activity. Furthermore, GNS is not able to substitute for LIF and
promotes the clonal expansion of ESCs in serum (Supporting
Information Fig. S3A), nor does it affect cloning efficiency in
the presence of LIF (Fig. 3B), consistent with a delay rather
than a complete block in differentiation.
O-GlcNAc Levels Do Not Affect Transition of Na€ıve
Cells to a Primed State
Recent work has suggested that O-GlcNAcylation of Oct4 can
maintain ESCs by regulation of downstream na€ıve state
markers like Nanog, Rex1, Klf2, Klf5 and others [11]. When
cultured in the presence of serum and LIF, ESC populations
consist of mixed na€ıve and primed cells, but in serum-free
N2B27 monolayer differentiation conditions the transcripts for
the na€ıve markers decline sharply after 24 hours and the
cells proceed to differentiate. To test whether this early transi-
tion is affected by O-GlcNAc levels we used the OCRG9 line,
expressing GFP under the control of the endogenous Rex1
locus. Under control conditions, OCRG9 cells become GFP
negative at day 2 of differentiation (the delay between loss of
Rex1 mRNA and loss of GFP is due to the stability of the
latter). GNS-treated OCRG9 cells lost expression of Rex1-GFP
at the same rate as the control (DMSO-treated) cells (Fig. 3C).
The transition from na€ıve to primed state is mediated by the
actions of the Erk1/2 kinases downstream of fibroblast growth
factor (Fgf) signaling. Recent work in Drosophila has identified
Figure 1. Global protein O-GlcNAcylation in embryonic stem cells (ESCs). (A): Whole-cell lysates of ESCs and cells at various stages of
neural differentiation were blotted for O-GlcNAc levels. No major changes are detectable in the most abundant bands. (B): Two-
dimensional gels of nuclear extracts blotted for O-GlcNAcylation. The overall level of O-GlcNAc is reduced in differentiation conditions
whereas a cluster of basic proteins is prominent in the Day 1 sample. (C): Dose-dependent increase in protein O-GlcNAcylation after 24
hours treatment with 1 mM GNS. (D): Undifferentiated and 3-day neural differentiated ESCs in DMSO or GNS were immunoprecipitated
with antibody against O-GlcNAc (RL-2) and succinylated WGA beads or antibody against Sox2 then blotted for Sox2 or Sox2 GlcNAcylated
at S248. GNS increases O-GlcNAc levels on Sox2, especially on day 3. (E): Measurement of apoptotic cells (pink) after 24 hours of vehicle
(DMSO) or 1 mM GNS treatment shows no difference in apoptosis levels. (F): ESC proliferation in vehicle (DMSO), the Oga inhibitors
Thiamet G, and GNS or its inactive stereoisomer, GalNacstatin C (all at 1 mM). Abbreviations: GNS, GlcNAcstatin C; O-GlcNAc, O-linked
N-acetylglucosamine.
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a requirement for O-GlcNAcylation for Erk1/2 signal transduc-
tion downstream of Fgf receptor [30]. However, consistent
with a normal transition to the primed state, we did not
detect any changes in the profile of Erk1/2 phosphorylation in
GNS-treated cells (Supporting Information Fig. S3B), suggest-
ing that the signal regulating transition of na€ıve cells to
primed pluripotency is unaltered by increased O-GlcNAc
levels.
This is further confirmed by quantitative RT-PCR for other
na€ıve cell markers Nanog, Rex1/Zfp42, Esrrb, and Dppa3
(Fig. 3D, Supporting Information Fig. S3C) as well as the tran-
sient upregulation of the epiblast marker Fgf5 in EB differen-
tiation (Fig. 3E). Taken together, these results indicate that O-
GlcNAc levels do not affect the initial events of ESC
differentiation.
In order to test this hypothesis further we performed a
microarray experiment to measure GNS’s effect on global
transcriptional changes during the transition of na€ıve pluripo-
tent cells to a primed state. We treated ESCs with DMSO or
GNS for 24 hours either in ESC media or in neural differentia-
tion conditions and compared gene expression between treat-
ments. Principal component analysis showed that the change
from self-renewal media to monolayer differentiation media
(including serum withdrawal) causes a major effect on global
gene expression (37%). This is reflected in the clustering of
the most significantly regulated genes that change their
expression from ESCs to day 1 of differentiation irrespective
of GNS (Fig. 3F). We then compared the changes in gene
expression during the first 24 hours of differentiation in the
presence of GNS or DMSO compared to undifferentiated
ESCs. This revealed that a great majority of the genes are
common to the two conditions (Fig. 3G), consistent with the
hypothesis that na€ıve-to-primed transition is unaffected by O-
GlcNAc levels. Many of the genes downregulated (fold change
>1.2, p< .05) in both vehicle and GNS samples belong to
pathways regulating ESC self-renewal (i.e., MAPK, Jak/Stat and
Tgfb superfamily; Table 1) and include Bmp4, Tgfb1 and down-
stream targets Id1, Id2, Id3; Stat3 and downstream target
Socs3 as well as transcription factors associated with na€ıve
pluripotency (Klf2, 3, 4, and 5, Nanog, Rex1/Zfp42). Common
upregulated genes include neural and mesodermal early dif-
ferentiation regulators (Otx2, Tbx4, Neurogenin3, NeuroD1,
and NeuroD4) as well as primed pluripotency epiblast marker
Fgf5, consistent with our RT-qPCR results. In total, 45 genes
from our set also belong to the Plurinet network of
pluripotency-related markers [31], 20 of which are
Figure 2. GlcNAcstatin treatment impairs embryonic stem cell (ESC) differentiation. (A): The proportion of Sox1GFP expressing neural
progenitors is decreased following GNS treatment during differentiation of 46C cells. (B): 46C cells retain expression of Oct4 when differ-
entiated in the presence of GNS while control cells differentiate into neural progenitors. Scale bar5 50 mm. (C): Oct4GiP cells retain
Oct4-GFP expression at higher levels in differentiation conditions compared to vehicle only controls. (D–F): ESCs were differentiated as
embryoid bodies in the presence of DMSO or GNS for 3 or 5 days then assayed for expression of endodermal marker BMP2 (D) or mes-
odermal markers Brachyury (E) or Eomesodermin (F) by RT-qPCR. Mean6 SEM from n5 3 experiments. Abbreviations: DAPI, 40,6-diami-
dino-2-phenylindole; GFP, green fluorescent protein; GNS, GlcNAcstatin C.
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upregulated in ESCs, and 25 are upregulated in the day 1
samples (Supporting Information Tables S3 and S4, respec-
tively). This result confirms that raised O-GlcNAc levels do not
affect the expression of genes controlling the onset of differ-
entiation in serum-free monolayer.
Increased Protein O-GlcNAcylation Does Not Interfere
With Phosphorylation of Major Signaling Pathways in
ESCs
O-GlcNAc is frequently attached to serine and threonine resi-
dues that can also be phosphorylated and for many proteins
this reciprocal relationship (often described as a “Yin-Yang”)
regulates their activity. To investigate whether increased O-
GlcNAc levels affect the global phosphorylation of proteins in
ESCs we compared the global phospho-serine and phospho-
threonine levels of ESC protein extracts treated with various
concentrations of GNS. Unlike global O-GlcNAc levels that
showed a dose-dependent increase, protein phosphorylation
levels remained relatively constant, suggesting that the major-
ity of ESC phosphosites are not occupied by O-GlcNAc (Sup-
porting Information Fig. S4A). This result, however, could
reflect a high abundance of constitutively phosphorylated pro-
teins in these cells that conceal significant changes in less
abundant and more dynamically regulated phosphoproteins.
We therefore focused our attention on protein kinases as
these proteins are often dynamically regulated by phosphoryl-
ation and mediate numerous important cellular responses. We
analyzed kinase phosphorylation in whole-cell lysates from
ESCs treated for 24 hours with either DMSO or GNS using a
protein kinase array. However, none of the 46 kinase sites
Figure 3. Increased O-GlcNAcylation does not affect na€ıve-primed embryonic stem cell (ESC) transition. (A): 46C ESCs were cultured in
the absence of LIF overnight and then stimulated with either LIF or the LIF receptor antagonist hLIF-05 in the presence of either DMSO
or GNS, then blotted for phospho-Stat3 (Y705). GNS treatment does not interfere with the ability of LIF to stimulate Stat3 phosphoryla-
tion and does not cause Stat3 phosphorylation in the absence of LIF. (B): GNS or Oga knockdown does not affect the ability of ESCs to
form undifferentiated colonies, while inhibition or knockdown of Ogt results in cell death. 4Ac: 4-Acetyl-5S-GlcNAc (Ogt inhibitor). (C):
OCRG9 ESCs (Rex1EGFP reporter line) were differentiated in N2B27 for 2 days in vehicle or GNS and analyzed by flow cytometry for
EGFP fluorescence. GlcNAcstatin treatment does not affect the loss of na€ıve marker Rex1. (D): Quantitative RT-PCR analysis during
monolayer differentiation shows that expression of the na€ıve marker Nanog is lost at equivalent rates in the presence of vehicle
(DMSO; black bars) or GNS (white bars). (E): Upregulation of the primed pluripotency marker Fgf5 is unaffected by GNS treatment (D
and E, n5 3, mean6 SEM). (F): Hierarchical clustering (using Euclidean distance with complete linkage agglomeration method) of sam-
ples based on the top 31 differentially expressed genes (ranked by p-value) separates the samples according to the stage of differentia-
tion and shows clustering of genes that contribute to differentiation. (G): Pairwise comparison of genes regulated during the first 24
hours of differentiation in vehicle (DMSO) or GNS (fold change >1.2, p< .05). Abbreviation: GNS, GlcNAcstatin C.
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profiled showed a significant change in their basal level of
phosphorylation by GNS (Supporting Information Fig. S4B)
indicating that the ESC kinome is not significantly affected by
the Yin-Yang interplay between O-GlcNAc and phosphate.
Raised O-GlcNAc Levels Affect Transcription
of Repressed Genes in ESCs
We then analyzed ESCs treated for 24 hours with DMSO or
GNS by microarrays, using Ranked Product analysis—a method
better at detecting changes in gene expression from small
number of replicates than the more commonly used Signifi-
cance Analysis of Microarrays or Analysis of Variance methods
[32]. Using a Ranked Product p-value< .05 we identified 971
differentially regulated genes. Of these, 516 were upregulated
following GNS treatment and 455 were downregulated. Two
of the most significantly regulated genes are Ogt and Oga
(Fig. 4A). Using RT-qPCR we found that Ogt expression is sig-
nificantly reduced within 1 hour of treatment with GNS,
whereas Oga upregulation appears slower (Fig. 4B, 4C). The
regulation of Oga and Ogt by O-GlcNAc levels is also reflected
at the protein level within 24 hours of treatment with GNS
(Supporting Information Fig. S4C) or by knockdown of Ogt or
Oga using siRNA (Fig. 4D).
One other gene that stood out from this analysis is Zscan4
(Fig. 4A). This gene has previously been associated with telo-
mere maintenance in ESCs [33] and is associated with a sub-
population of cells similar to that of the recently described
“2C” state of privileged developmental plasticity, existing
within ESC cultures [34–36]. 2C cells differ in gene expression
from ESCs in that they express genes associated with zygotic
genome activation and have been demonstrated to be totipo-
tent (giving rise to extraembryonic as well as embryonic tis-
sues in chimeras) [36]. Transcripts marking this subpopulation
include retrotransposons normally repressed by epigenetic
mechanisms as well as chimeric transcripts of genes with
junctions to murine endogenous retrovirus with leucine tRNA
primer (MERVL) elements [36]. Interestingly, the number of
genes upregulated in the GNS-treated samples was much
larger than the DMSO samples, both for the genes enriched
in ESCs and for genes enriched in Day 1 differentiating cells.
We therefore performed pairwise comparisons between the
ESC and Day 1 samples in DMSO or GNS treatment for the
most regulated genes (p< .05, fold change >2). The majority
of genes with expression higher in ESCs than Day 1 (80%;
348/437) were similarly regulated both in DMSO and GNS.
However, of the remaining 20% (those that were not common
to GNS and DMSO), nearly three times more genes were
higher in the GNS sample than in DMSO (65 vs. 24; Fig. 5A).
Similarly, the majority of the genes expressed at higher level
in Day 1 samples compared to ESCs are common to GNS and
DMSO (75%; 160/214), but of those differentially regulated
between the treatments, those regulated by GNS outnum-
bered those regulated by DMSO by a factor of 3.5 (42 vs. 12;
Fig. 5A). This result suggests that GNS treatment causes a
general increase in gene expression both in ESCs and early
differentiating cells (Fig. 3G). We then turned to GSEA for fur-
ther mining of our expression data. Search of the whole
MSigDB and GeneSigDB databases using GSEA did not reveal
a significant enrichment for any gene set so we created our
own gene sets from publicly available microarray and ChIP-
seq data as published in relevant papers. We focused our
attention to targets of the ESC core pluripotency network [37,
38] and genes regulated by the Polycomb group [39–41].
Although there was no significant enrichment for polycomb
complex 1 or 2 targets in our dataset (Supporting Information
Table S6), a specific subset of polycomb target genes, desig-
nated as Polycomb-repressed (PRCR) [39], is highly
Table 1. KEGG pathway analysis of the genes significantly regulated during the first 24 hours of embryonic stem cell differentiation
irrespective of GlcNAcstatin C treatment
Regulation Term Count % of genes in group p-Value Benjamini
Up in ES Focal adhesion 57 0.3 2.30E-12 3.90E-10
Up in ES Lysosome 39 0.2 1.90E-10 1.60E-08
Up in ES ECM-receptor interaction 28 0.2 5.70E-08 3.10E-06
Up in ES Regulation of actin cytoskeleton 45 0.2 1.70E-05 7.20E-04
Up in ES TGF-beta signaling pathway 24 0.1 2.80E-05 9.20E-04
Up in ES Pathways in cancer 59 0.3 3.90E-05 1.10E-03
Up in ES Tight junction 31 0.2 6.70E-05 1.60E-03
Up in ES Leukocyte transendothelial migration 28 0.2 1.10E-04 2.20E-03
Up in ES MAPK signaling pathway 49 0.3 1.50E-04 2.70E-03
Up in ES ARVC 20 0.1 2.50E-04 4.20E-03
Up in ES Small cell lung cancer 21 0.1 5.00E-04 7.50E-03
Up in ES Other glycan degradation 8 <0.1 7.50E-04 1.00E-02
Up in ES Glycosphingolipid biosynthesis 7 <0.1 2.10E-03 2.60E-02
Up in ES Endocytosis 36 0.2 2.60E-03 3.00E-02
Up in ES Jak-STAT signaling pathway 29 0.2 2.70E-03 3.00E-02
Up in ES HCM 19 0.1 2.90E-03 3.00E-02
Up in ES Glycosphingolipid biosynthesis 7 <0.1 3.20E-03 3.10E-02
Up in ES ErbB signaling pathway 19 0.1 4.30E-03 3.90E-02
Up in ES Amino sugar and nucleotide sugar metabolism 12 0.1 5.50E-03 4.70E-02
Up in ES Galactose metabolism 9 <0.1 5.80E-03 4.70E-02
Up in ES Dorso-ventral axis formation 8 <0.1 6.30E-03 4.90E-02
Up in Day 1 Steroid biosynthesis 11 0.1 1.90E-08 3.40E-06
Up in Day 1 Terpenoid backbone biosynthesis 8 0.1 1.30E-05 1.10E-03
Up in Day 1 Biosynthesis of unsaturated fatty acids 9 0.1 2.60E-04 1.50E-02
Up in Day 1 Pathways in cancer 38 0.3 6.90E-04 3.00E-02
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy.
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significantly enriched in ESCs treated with GNS compared to
the vehicle control (Fig. 5B, Table 2). Strikingly, we also
detected highly significant enrichment in the GNS-treated
samples for the gene sets corresponding to the 2C population
(the 2C sets as described previously [36]) as well as the gene
set “2C-MERVL1” which comprises the genes from the 2C set
that contain MERVL chimeric transcripts. The enrichment of
2C transcripts is highly significant both in undifferentiated
ESCs and in Day 1 differentiation samples treated with GNS
compared to their respective vehicle controls (Fig. 5C, 5D,
Table 2, Supporting Information Tables S6 and S7). We vali-
dated the upregulation of three 2C associated genes (Zfp352,
Tdpoz3, and Zscan4) by Oga knockdown and GNS in ESCs
using quantitative RT-PCR and show a consistent upregulation
for all three (Fig. 5C, Supporting Information Fig. S5A–S5C).
These results therefore indicate that increased O-GlcNAc lev-
els result in increased expression of epigenetically repressed
genes, including those characteristic of a totipotent 2C state.
DISCUSSION
Our results demonstrate that ESC differentiation is reduced
under conditions of increased O-GlcNAc signaling and pinpoint
the deficit to a stage in differentiation after the loss of naive
pluripotency but before the definitive differentiation as
marked by the loss of Oct4 expression. Using a range of dif-
ferentiation protocols we found a delay in the onset of differ-
entiation toward embryonic lineages. We report that Oga
inhibition does not affect the upregulation or downregulation
of the genes known to be regulated early during differentia-
tion, but results in prolonged expression of the pluripotency
master regulator Oct4 and a delay in the acquisition of stable
neural differentiation marker Sox1. Therefore, our results
clearly demonstrate that Oga inhibition does not affect the
transition from the na€ıve to the primed state, indicating
instead that elevated O-GlcNAc levels affect differentiation
progression at a later stage. Taken together, our data show a
clear effect of Oga inhibition on the initiation of ESC differen-
tiation that affects multiple somatic lineages.
We also report that Oga inhibition does not interfere with
the steady-state phosphorylation levels of several key kinases,
suggesting that the main mechanism of action operates down-
stream of the signal transduction machinery. The fact that the
phosphorylation status of kinases is unaffected by GNS in this
context does not, however, preclude changes in kinase activity,
localization, or interaction with substrates. It also remains pos-
sible that the stimulated, maximal phosphorylation levels of
some of these kinases will be affected by elevated O-GlcNAc
despite no obvious effects at the basal phosphorylation levels.
An early study of Oga inhibition during ESC differentiation
identified a deficit in spontaneous cardiomyocyte generation
in EBs [12]. In that study a different, less specific Oga inhibi-
tor was added to 5-day-old differentiating EBs, when ESC
markers are already lost and the cells have already committed
to differentiating, highlighting a role for Oga in the commit-
ment of mesodermal cells to the cardiomyocyte lineage. Our
data extend and refine this previous observation by determin-
ing an earlier role in the exit from the pluripotent state.
More recently, a report demonstrated a role for the O-GlcNAc
modification of Oct4 in the onset of ESC differentiation [11].
Our results are consistent with those findings, although we
find that na€ıve ESC markers decline normally under elevated
O-GlcNAc conditions, demonstrating that the earliest events
in ESC differentiation are not O-GlcNAc dependent.
A number of recent papers have linked the O-GlcNAc
transferase to the regulation of epigenetic regulators [16–18,
42]. Our gene expression analysis has revealed that following
Oga inhibition a number of repressed genes become acti-
vated. Gene set enrichment analysis showed a significant
enrichment for a specific subset of polycomb repressor com-
plex target genes, as well as genes associated with the early
zygotic genome activation and retrovirus-like elements. This
latter gene expression signature is thought to mark a develop-
mentally privileged ESC subpopulation capable of differentia-
tion into extraembryonic lineages [35, 36]. These genes are
Figure 4. O-linked N-acetylglucosamine levels control Ogt and
Oga levels in embryonic stem cells (ESCs). (A): Ranked product
analysis of genes regulated in ESCs by GlcNAcstatin C treatment.
Blue: significantly upregulated genes; yellow: significantly downre-
gulated genes. (B): Validation of Ogt regulation by RT-qPCR
(n5 4, mean6 SEM). (C): Validation of Oga expression by
RT-qPCR (n5 4, mean6 SEM). (D): RNAi knockdown of Ogt and
Oga results in a negative feedback regulation on the expression
of Oga and Ogt, respectively. *, p< .05; **, p< .01 compared to
t5 0 (t test).
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under the control of epigenetic regulators of gene expression
and their expression can be induced by interfering with histone
acetylation and methylation, either pharmacologically or by
genetic deletion of key enzymes [36]. Our findings therefore
suggest that the levels of O-GlcNAc in cells influence global
gene expression regulated by major epigenetic mechanisms
such as histone modifications and DNA methylation, and are
consistent with a differentiation delay observed in ESCs treated
with an inhibitor of histone deacetylases [43]. Intriguingly, Oga
has been shown to possess histone acetyltransferase (HAT)
activity in vitro [44] and this activity is distinct from its GlcNA-
case function. It is therefore likely that although inhibition of
Oga’s O-GlcNAcase activity by GNS raises O-GlcNAc levels and
leads to feedback Oga upregulation, it does not affect the pro-
tein’s HAT activity (as has been shown for the less specific
inhibitor Streptozotocin [44]). This could possibly lead to
increased histone acetylation and the derepression of tran-
scription we observe, although the observation that 2C genes
were upregulated even when Oga protein levels are reduced
by siRNA (Fig. 5E) indicates that this is not the main mecha-
nism in this case. The negative feedback regulation from
increased O-GlcNAc levels to a reduction in Ogt protein levels
may also contribute to the phenotypes observed, by disrupting
the formation of some of its protein complexes. O-GlcNAc can
itself modify histones [45] and promote transcriptional activa-
tion [46], so the precise mechanism by which gene expression
is regulated by O-GlcNAc levels is likely to be complex and
involve many, possibly redundant molecular players.
Figure 5. Oga inhibition results in a broad genomic transcriptional derepression. (A): Bar charts showing the number of unique genes
upregulated in ESCs or in Day 1 differentiation in the DMSO or GNS samples (p< .05, fold change >2). (B): Gene set enrichment analy-
sis (GSEA) shows that GNS treatment results in an upregulation of the “Polycomb repressed” gene set. (C): GSEA showing enrichment of
the 2C gene set in the GNS-treated ESCs. (D): The 2C gene set is also enriched in the GNS-treated Day 1 differentiating cells. (E): RT-
qPCR validation of the upregulation of three genes from the 2C cohort by knockdown of Oga (n5 3, mean6 SEM) *, p< .05. Abbrevia-
tion: GNS, GlcNAcstatin C.
Table 2. Gene sets significantly enriched in GlcNAcstatin C or DMSO-treated embryonic stem cell or Day 1 differentiation samples
Name Size
Enrichment
score
Normalized
enrichment
score
Nominal
p-value
False discovery rate
q-value Enrichment in
2C-MERVL1 45 0.85 1.85 <.001 <0.001 ES GNS versus ES DMSO
2C 466 0.66 1.78 <.001 0.001 ES GNS versus ES DMSO
PRCR 1,331 0.47 1.31 <.001 0.038 ES GNS versus ES DMSO
2C 466 0.39 1.25 .006 0.033 Day 1 GNS versus Day 1 DMSO
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CONCLUSIONS
In conclusion, our results demonstrate that ESC differentiation
is delayed under conditions of increased O-GlcNAc signaling
and pinpoint the delay to a stage in differentiation after the
loss of naive pluripotency but before commitment to differen-
tiation as marked by the loss of Oct4 expression. We used
defined media and short timescales to minimize the possibility
of multiple effects on several interacting cell types, and found a
measurable, significant defect in the progression toward differ-
entiation. We attribute this differentiation defect to a disrup-
tion of the normal function of global activation and repression
complexes, such as the histone deacetylases, polycomb group,
and Ten-eleven translocation proteins as well as direct effects
of Oga and Ogt on chromatin.
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